Genomic Profiling in Cancer Patients

Status:	Recruiting
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	2/8/2019
Start Date:	January 2013
End Date:	January 2020
Contact:	David Hyman, MD
Phone:	646-888-4544

The purpose of this study is to determine whether certain genes in cancer may be abnormal.
When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not
inherited (passed down from parents) but happen after birth in the cancer itself. Most
cancers have many mutations. Some of these mutations are important for the cancer cells to
survive while others are not. The goal of this study is test cancer for certain mutations
using leftover tumor tissue from a previous surgery or biopsy. Participants will also be
asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that
contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental
cancer treatment. Understand how the genes in the tumor change overtime in response to
targeted cancer treatment.

Inclusion Criteria:

Part A:

- Patients with cancer or other related disorders

Part B:

- Patients successfully registered to Part A of (MSKCC IRB # 12-245)

- Prior written approval for patient consent obtained from Director of the Center fo
Molecular Oncology, or a Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

- Patient must be receiving ongoing care at MSK or an Alliance/Affiliate site.

- Patient must have successfully consented to Part A of this study.

Exclusion Criteria:

- Unwilling or unable to provide informed consent.

We found this trial at

sites

Hartford Healthcare Cancer Institute @ Hartford Hospital

Hartford, Connecticut 06102

Phone: 860-972-2803

from

Hartford, CT